{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:08:24Z","timestamp":1793678904438,"version":"4.5.1"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)\/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1\u2013selected tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The GO30103 open-label, first-in-human phase 1a\/1b dose-escalation and dose-expansion nonrandomized controlled trial was conducted at 13 sites in 6 countries (Australia, Canada, France, Korea, Spain, and the US). The start dates were May 23, 2016, for phase 1a and October 11, 2016, for phase 1b. Patients were aged 18 years or older with measurable disease at baseline. The clinical cutoff date was October 1, 2021. Data analysis was performed on January 24, 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients received fixed-dose intravenous tiragolumab on day 1 of each 21-day cycle (2 mg escalating to 1200 mg) in phase 1a, plus fixed-dose intravenous atezolizumab (1200 mg every 3 weeks) in phase 1b. Patients were treated until disease progression, loss of clinical benefit, or development of unacceptable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end points included the safety, tolerability, and recommended phase 2 dose (RP2D) of tiragolumab or combination tiragolumab plus atezolizumab. The secondary end point included the investigator-assessed objective response rate (ORR). Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the phase 1a (n\u2009=\u200924) and 1b (n\u2009=\u200949) dose-escalation cohorts, the median age was 60 (range, 40-77) and 54 (range, 25-81) years, respectively. More than half of patients were women (14 of 24 [58%] and 25 of 49 [51%]), and more than a third (10 [42%] and 18 [37%]) had received 4 or more prior cancer therapies. No dose-limiting toxicities occurred, and the maximum tolerated dose of tiragolumab was not reached (NR). The most frequent treatment-related adverse events (AEs) were fatigue (5 of 24 [21%]) in phase 1a and pruritus (5 of 49 [10%]) in phase 1b; the majority of AEs were grade 1 or 2. Immune-mediated AEs occurred in 4 of 24 (17%) and 29 of 49 (59%) patients during phases 1a and 1b, respectively (primarily grade 1 or 2). The RP2D of tiragolumab was 600 mg intravenously every 3 weeks, which was tested in phase 1b dose expansion. The confirmed ORR was 0% during phase 1a, with evidence of antitumor activity in 6% of patients (n\u2009= 3) during phase 1b. The safety profile of combination tiragolumab plus atezolizumab in phase 1b was similar in the dose-escalation and dose-expansion cohorts. The confirmed ORR was 46% (6 of 13) in the non\u2013small cell lung cancer (NSCLC) cohort (median duration of response [DOR], NR) and 28% (5 of 18) in the esophageal cancer (EC) cohort (median DOR, 15.2 [95% CI, 7.0 to NR] months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this nonrandomized controlled trial, tiragolumab was well tolerated\u2009with or without\u2009atezolizumab; no new safety signals were observed. Preliminary antitumor activity was demonstrated for the combination regimen in patients with cancer immunotherapy\u2013naive metastatic NSCLC or EC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02794571\">NCT02794571<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3867","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:36:08Z","timestamp":1695915368000},"page":"1574","source":"Crossref","is-referenced-by-count":83,"title":["Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors"],"prefix":"10.1001","volume":"9","author":[{"given":"Tae Won","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[{"name":"HonorHealth Research and Innovation Institute, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bendell","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee"},{"name":"now with F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Jonsson Comprehensive Cancer Center, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippe A.","family":"Cassier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gil-Martin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata S.","family":"Patil","sequence":"additional","affiliation":[{"name":"Biomarkers, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Jin","sequence":"additional","affiliation":[{"name":"Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Hoang","sequence":"additional","affiliation":[{"name":"Clinical Science, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mendus","sequence":"additional","affiliation":[{"name":"Clinical Science, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wen","sequence":"additional","affiliation":[{"name":"Safety Science, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Meng","sequence":"additional","affiliation":[{"name":"Clinical Science, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi230050r1","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"coi230050r2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms21072532","article-title":"Immunotherapy in renal cell carcinoma: the future is now.","volume":"21","author":"Deleuze","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"coi230050r3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/pcmr.v33.3","article-title":"Targeted therapy and immunotherapy: emerging biomarkers in metastatic melanoma.","volume":"33","author":"LoRusso","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"14","key":"coi230050r4","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.3390\/cancers13143596","article-title":"The next generation of combination cancer immunotherapy: epigenetic immunomodulators transmogrify immune training to enhance immunotherapy.","volume":"13","author":"Mokhtari","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi230050r5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"issue":"6","key":"coi230050r6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"coi230050r7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle.","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"issue":"4","key":"coi230050r8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.","volume":"10","author":"Chiang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"coi230050r9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"5","key":"coi230050r10","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients.","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"issue":"20","key":"coi230050r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"coi230050r12","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.3390\/cancers13184632","article-title":"Immunotherapy for esophageal cancers: what is practice changing in 2021?","volume":"13","author":"Puhr","year":"2021","journal-title":"Cancers (Basel)"},{"key":"coi230050r13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review.","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"coi230050r14","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"39","key":"coi230050r15","doi-asserted-by":"publisher","first-page":"63669","DOI":"10.18632\/oncotarget.v7i39","article-title":"Expression of immune checkpoints in T cells of esophageal cancer patients.","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"coi230050r16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer.","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"coi230050r17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-21-2780","article-title":"A phase 1a\/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors.","volume":"28","author":"Mettu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi230050r18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2810007\/jamaoncology_kim_2023_oi_230050_1699901565.48076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:03:04Z","timestamp":1700150584000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2810007"}},"subtitle":["A Phase 1a\/1b Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3867","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}